Anti-Collagen III antibody [FH-7A] (Ab6310)

特异性

ab6310 specifically recognizes collagen type III from human and rat origin. It does not recognize collagen types I, II, IV, V, VI and X.

Anti-Collagen III antibody [FH-7A] (ab6310) is a House Mouse Monoclonal antibody and is validated for use in Dot, ELISA, ICC/IF, IHC-Fr, IHC-P, WB in human samples. Anti-Collagen III antibody [FH-7A] (ab6310) has been cited over 172 times in peer reviewed journals and is trusted by the scientific community. Abcams high quality validation processes ensure Anti-Collagen III antibody [FH-7A] (ab6310) has high sensitivity and specificity. Anti-Collagen III antibody [FH-7A] (ab6310) has 13 independent reviews from customers. Anti-Collagen III antibody [FH-7A] (ab6310) specifically detects Collagen III (UniProt ID: P02461; Molecular weight: 95kDa) and is sold in 50 uL selling sizes. Collagen III is a critical fibrillar collagen that plays a significant role in the structural integrity of various tissues, including the skin, lungs, and blood vessels. Alterations in Collagen III expression are associated with several diseases. For instance, mutations in the COL3A1 gene, which encodes Collagen III, can lead to Ehlers-Danlos syndrome type IV, a condition characterized by fragile blood vessels and organs. Additionally, abnormal Collagen III deposition is implicated in fibrotic diseases, such as liver cirrhosis and pulmonary fibrosis, where excessive collagen accumulation disrupts normal tissue architecture. Understanding Collagen III's role in these diseases is crucial for developing targeted therapies and improving patient outcomes. Type III collagen, [a1(III)]3,is an approx. 300 kDa molecule, found predominantly in skin, blood vessels, liver, placenta, tongue, and thymus. Collagen type III forms cofibrils with type I and/or V collagens in a number of tissues of mesenchymal origin, such as skin, tendon, ligaments, and bone. This collagen type is involved, directly or indirectly in several genetic diseases, including Ehlers-Danlos type IV disease. This product was changed from ascites to tissue culture supernatant on 17 May 2019. Please note that the dilutions may need to be adjusted accordingly. If you have any questions, please do not hesitate to contact our scientific support team.